EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 14th, 2022 • Aisling Capital IV, LP • Pharmaceutical preparations
This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.0001 per share, of Viracta Therapeutics, Inc. (this “Agreement”), is being filed, and all amendments thereto will be filed by Aisling Capital IV, LP as the designated filer on behalf of each of the persons and entities named below that is named as a reporting person in such filing in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 14th, 2022 • Aisling Capital IV, LP • Biological products, (no disgnostic substances)
This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.0001 per share, of Elevation Oncology, Inc. (this “Agreement”), is being filed, and all amendments thereto will be filed by Aisling Capital IV, LP as the designated filer on behalf of each of the persons and entities named below that is named as a reporting person in such filing in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
BOARD OBSERVER AGREEMENTBoard Observer Agreement • October 19th, 2018 • Aisling Capital IV, LP • Pharmaceutical preparations • Delaware
THIS BOARD OBSERVER AGREEMENT (this “Agreement”) is made as of October 17, 2018 (the “Effective Date”), between MARKER THERAPEUTICS, INC., a Delaware corporation formerly known as TapImmune Inc., a Nevada corporation (the “Company”), and AISLING CAPITAL IV, LP (the “Shareholder”). Unless otherwise specified herein, all of the capitalized terms used herein are defined in Section 3 hereof.
JOINT FILING AGREEMENTJoint Filing Agreement • October 19th, 2018 • Aisling Capital IV, LP • Pharmaceutical preparations
Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13D to which this Agreement is attached as an Exhibit, and any amendments thereto, will be filed with the Securities and Exchange Commission jointly on behalf of the undersigned. This Agreement may be executed in one or more counterparts.
